THE Pharmaceutical Society of Australia (PSA) released its 2025 Strategic Projects Impact Report last week, highlighting its key role in progressing the safe use of medicines and demonstrating collaborative, evidence-based initiatives.
The PSA's projects team has delivered more than 40 initiatives this year in collaboration with over 30 partners, cementing PSA's role as the national peak body driving the Quality Use of Medicines (QUM) agenda.
Pharmacists have been well supported through changes, with key education projects around palliative care, mental health first aid training and vaping reform.
National PSA President, Associate Professor Fei Sim, said translating policy into practice and equipping pharmacists to lead innovation has resulted in a future where pharmacists are fully enabled to provide person-centred care across all areas of practice.
"The Impact Report demonstrates PSA's unwavering commitment to excellence, collaboration, and measurable national impact in improving the quality use of medicines," she said.
"Pharmacists play a vital role in supporting symptom management, medicines optimisation, and continuity of care at the end of life, yet their expertise has not been systematically embedded across community and primary care settings.
"In addition to driving innovation through projects and pilots, we are committed to supporting the pharmacy workforce with education, training, and practice support regardless of policy decisions.
"This ensures pharmacists and pharmacy support staff have the confidence to meet regulatory requirements, ensuring clarity, consistency, and alignment with the needs of both consumers and our health system."
The report is available HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Nov 25
